secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001999371-25-002866
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics amends bylaws to enhance stockholder rights; sues Sandoz over RYZUMVI
--------------------------------------------------------------------------------

- Bylaws amended: written consent requirements eliminated; 20% threshold to call special meeting.
- Stockholder removal threshold reduced to simple majority; amendment threshold also reduced to simple majority.
- Filed patent infringement suit against Sandoz in NJ over ANDA for generic RYZUMVI; seeks injunction.
- Suit filed with partner FamyGen Life Sciences; Opus intends to vigorously enforce RYZUMVI IP rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000199937125002866/0001999371-25-002866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000199937125002866/ird-8k_031925.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-002866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer